VIVXF (Avivagen) Ending Cash Position: $0.01 Mil (As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avivagen Ending Cash Position?

Avivagen VIVXF -99.00% Ending Cash Position is $0.01 Mil as of Jul. 2023.

Avivagen's Ending Cash Position for the quarter that ended in Jul. 2023 was $0.01 Mil.

Avivagen's quarterly Ending Cash Position declined from Jan. 2023 ($0.02 Mil) to Apr. 2023 ($0.01 Mil) but then stayed the same from Apr. 2023 ($0.01 Mil) to Jul. 2023 ($0.01 Mil).

Avivagen's annual Ending Cash Position increased from Oct. 2020 ($0.50 Mil) to Oct. 2021 ($1.13 Mil) but then declined from Oct. 2021 ($1.13 Mil) to Oct. 2022 ($0.21 Mil).

Avivagen Ending Cash Position Related Terms

Avivagen Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Avivagen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Ending Cash Position Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 0.82 0.50 1.13 0.21

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.21 0.02 0.01 0.01

Avivagen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Avivagen's Ending Cash Position for the fiscal year that ended in Oct. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.029+-0.817
=0.21

Avivagen's Ending Cash Position for the quarter that ended in Jul. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.012+0.001
=0.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.01 Mil mean?
Avivagen (VIVXF) has a Ending Cash Position of $0.01 Mil as of Jul. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Avivagen and its competitors.
Is Avivagen's Ending Cash Position too high?
Avivagen's current Ending Cash Position is $0.01 Mil.
How does Avivagen's Ending Cash Position compare to DMKPQ and MJNE?
Avivagen's Ending Cash Position of $0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Avivagen and its competitors. Avivagen's current Ending Cash Position is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Ending Cash Position of $0.01 Mil. The current Ending Cash Position is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Avivagen (VIVXF), the current Ending Cash Position is $0.01 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.